1. Home
  2. CAI vs TGTX Comparison

CAI vs TGTX Comparison

Compare CAI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caris Life Sciences Inc.

CAI

Caris Life Sciences Inc.

N/A

Current Price

$23.05

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.33

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAI
TGTX
Founded
2008
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.5B
IPO Year
2025
2008

Fundamental Metrics

Financial Performance
Metric
CAI
TGTX
Price
$23.05
$64.33
Analyst Decision
Buy
Buy
Analyst Count
14
7
Target Price
$34.23
★ $77.50
AVG Volume (30 Days)
★ 3.8M
1.9M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
69.79
★ 1746.67
EPS
0.05
★ 0.52
Revenue
★ $812,033,000.00
$2,785,000.00
Revenue This Year
$28.81
$61.95
Revenue Next Year
$19.11
$35.55
P/E Ratio
$477.70
★ $124.76
Revenue Growth
★ 96.97
N/A
52 Week Low
$14.19
$26.76
52 Week High
$36.50
$68.03

Technical Indicators

Market Signals
Indicator
CAI
TGTX
Relative Strength Index (RSI) 31.26 64.72
Support Level $21.99 $51.70
Resistance Level $23.66 N/A
Average True Range (ATR) 2.05 3.49
MACD -1.17 0.65
Stochastic Oscillator 3.45 73.78

Price Performance

Historical Comparison
CAI
TGTX

About CAI Caris Life Sciences Inc.

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: